Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
RICHMOND, Virginia - A study presented Tuesday at the Keystone Symposia’s Neurodegeneration conference shows that XPro treatment may prevent Alzheimer’s-like pathology in mice following traumatic brain injury (TBI), according to a press release from INmune Bio, Inc. (NASDAQ: INMB), a $182 million market cap biotechnology company. The company’s stock has shown strong momentum with a 40% gain over the past six months, according to InvestingPro data.
Researchers from Virginia Commonwealth University demonstrated that TBI increases amyloid deposition in high-risk animals, while administration of XPro (pegipanermin) significantly reduced amyloid formation and improved brain function measures.
The study found that TBI triggered a temporary increase in TNFR1, BACE1, and Aβ42 expression in the hippocampus, peaking three days after injury before returning to baseline by day seven. When XPro was administered 30 minutes after injury, it inhibited solTNF/TNFR1 activity and prevented elevations in these markers.
"Our findings demonstrate that TBI exacerbates amyloidogenesis and behavioral deficits in the hippocampus through solTNF/TNFR1 signaling," said Dr. Kirsty Dixon, Associate Professor of Surgery at Virginia Commonwealth University, who led the research.
The study also showed that XPro treatment reduced intracellular neuronal amyloid accumulation in the hippocampus and improved neurological outcomes in treated animals.
Elliott Mufson, PhD, professor of neurobiology at Barrow Neurological Institute and a collaborator on the study, noted that XPro "targets neurobehavioral dysfunction resulting from brain trauma and age-related neurodegenerative disease."
TBI is a known risk factor for Alzheimer’s disease, particularly among elderly populations. The research suggests that targeting TBI-induced inflammation could potentially mitigate Alzheimer’s disease risk.
XPro is a tumor necrosis factor inhibitor currently in clinical trials. The treatment differs from available TNF inhibitors as it neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors. With analyst price targets ranging from $20 to $30, significantly above current trading levels, market experts maintain a bullish outlook on the company’s potential. Access detailed valuation metrics and comprehensive analysis through InvestingPro’s exclusive research tools.
The findings were presented in a poster session at the Keystone Symposia’s Neurodegeneration conference in Whistler, British Columbia. While the company maintains a strong balance sheet with more cash than debt, InvestingPro analysis indicates the company is not yet profitable, with analysts expecting continued losses this year. For detailed insights and 8 additional ProTips about INmune Bio’s financial health and market position, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, INmune Bio Inc. reported a net loss of $9.7 million for the first quarter of 2025, an improvement from the $11 million loss in the same period last year. The company’s earnings per share (EPS) exceeded expectations, coming in at -$0.43 compared to the forecasted -$0.49. Lucid Capital Markets initiated coverage on INmune Bio with a Buy rating, setting a price target of $25, highlighting the potential of their Alzheimer’s treatment, XPro. The treatment is currently under evaluation in the ongoing MINDFul Phase 2 trial, with results expected in June. The company maintains a strong cash position with $19.3 million, projected to support operations through the third quarter of 2025. INmune Bio’s focus on Alzheimer’s and prostate cancer treatments is expected to drive future growth. The company is also planning to file a Biologics License Application for its RDEB treatment, Cordstrom, in 2026. This comes as the company continues to advance its clinical trials, including the INKmune program for prostate cancer, which remains on track to complete enrollment this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.